Pamela Lucchesi

Prof. Pamela Lucchesi

New York Medical College

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2019 in Pharmacy
Verified
Journal Article
Open access
PDF file
Brian J PiperBrian J Piper
Brian J Piper
AAAlexandria A. Alinea
Alexandria A. Alinea
JWJohn R. Wroblewski
John R. Wroblewski
SGSara M. Graham
Sara M. Graham
DCDaniel Y. Chung
Daniel Y. Chung
MBMichael Bordonaro
Michael Bordonaro
Goodman and Gilman’s The Pharmacological Basis of Therapeutics (GGPBT) has been a cornerstone in the education of pharmacists, physicians, and pharmacologists for decades. The objectives of this study were to describe and evaluate the 13th edition of GGPBT on bases including: (1) author characteristics; (2) recency of citations; (3) conflict of interest (CoI) disclosure; (4) expert evaluation of chapters. Contributors’ (N = 115) sex, professional degrees, and presence of undisclosed potential CoI—as reported by the Center for Medicare and Medicaid’s Open Payments (2013–2017)—were examined. The year of publication of citations was extracted relative to Katzung’s Basic and Clinical Pharmacology (KatBCP), and DiPiro’s Pharmacotherapy: A Pathophysiologic Approach (DiPPAPA). Content experts provided thorough chapter reviews. The percent of GGPBT contributors that were female (20.9%) was equivalent to those in KatBCP (17.0%). Citations in GGPBT (11.5 ± 0.2 years) were significantly older than those in KatBCP (10.4 ± 0.2) and DiPPAPA (9.1 ± 0.1, p < 0.0001). Contributors to GGPBT received USD 3 million in undisclosed remuneration (Maximum author = USD 743,718). In contrast, DiPPAPA made CoI information available. Reviewers noted several strengths but also some areas for improvement. GGPBT will continue to be an important component of the biomedical curriculum. Areas of improvement include a more diverse authorship, improved conflict of interest transparency, and a greater inclusion of more recent citations.

Verified
Journal Article
Open access
PDF file
RCRachel Childers
Rachel Childers
PLPamela Lucchesi
Pamela Lucchesi
KGKeith Gooch
Keith Gooch
A hypofibrotic phenotype has been observed in cardiac fibroblasts (CFs) isolated from a volume overload heart failure model, aortocaval fistula (ACF). This paradoxical phenotype results in decreased ECM synthesis despite increased TGF-β presence. Since ACF results in decreased tissue stiffness relative to control (sham) hearts, this study investigates whether the effects of substrate stiffness could account for the observed hypofibrotic phenotype in CFs isolated from ACF. CFs isolated from ACF and sham hearts were plated on polyacrylamide gels of a range of stiffness (2 kPa to 50 kPa). Markers related to cytoskeletal and fibrotic proteins were measured. Aspects of the hypofibrotic phenotype observed in ACF CFs were recapitulated by sham CFs on soft substrates. For instance, sham CFs on the softest gels compared to ACF CFs on the stiffest gels results in similar CTGF (0.80 vs. 0.76) and transgelin (0.44 vs. 0.57) mRNA expression. The changes due to stiffness may be explained by the observed decreased nuclear translocation of transcriptional regulators, MRTF-A and YAP. ACF CFs appear to have a mechanical memory of a softer environment, supported by a hypofibrotic phenotype overall compared to sham with less YAP detected in the nucleus, and less CTGF and transgelin on all stiffnesses.

21 April 2021 in Journal of Biomechanical Engineering
Verified
Journal Article
Closed access
PDF file
RCRachel Childers
Rachel Childers
ATAaron J. Trask
Aaron J. Trask
JLJun Liu
Jun Liu
PLPamela Lucchesi
Pamela Lucchesi
KGKeith Gooch
Keith Gooch
Pressure overload (PO) and volume overload (VO) of the heart result in distinctive changes to geometry, due to compensatory structural remodeling. This remodeling potentially leads to changes in tissue mechanical properties. Understanding such changes is important, as tissue modulus has an impact on cardiac performance, disease progression, and influences on cell phenotype. Pressure–volume (PV) loop analysis, a clinically relevant method for measuring left ventricular (LV) chamber stiffness, was performed in vivo on control rat hearts and rats subjected to either chronic PO through Angiotensin-II infusion (4-weeks) or VO (8-weeks). Immediately following PV loops, biaxial testing was performed on LV free wall tissue to directly measure tissue mechanical properties. The β coefficient, an index of chamber stiffness calculated from the PV loop analysis, increased 98% in PO (n = 4) and decreased 38% in VO (n = 5) compared to control (n = 6). Material constants of LV walls obtained from ex vivo biaxial testing (n = 9–10) were not changed in Angiotensin-II induced PO and decreased by about half in VO compared to control (47% in the circumferential and 57% the longitudinal direction). PV loop analysis showed the expected increase in chamber stiffness of PO and expected decrease in chamber stiffness of VO. Biaxial testing showed a decreased modulus of the myocardium of the VO model, but no changes in the PO model, this suggests the increased chamber stiffness in PO, as shown in the PV loop analysis, may be secondary to changes in tissue mass and/or geometry but not an increase in passive tissue mechanical properties.

29 September 2019 in medRxiv
Verified
Preprint
Open access
PDF file
Brian J PiperBrian J Piper
Brian J Piper
AAAlexandria A. Alinea
Alexandria A. Alinea
JWJohn R Wroblewski
John R Wroblewski
SGSara M. Graham
Sara M. Graham
DCDaniel Y. Chung
Daniel Y. Chung
MBMichael Bordonaro
Michael Bordonaro
Objective: Goodman and Gilman’s The Pharmacological Basis of Therapeutics ( GG PBT) has been a cornerstone in the education of pharmacists, physicians, and pharmacologists for decades. The objectives of this report were to describe and evaluate the 13 th edition of GG PBT including: 1) author characteristics; 2) recency of citations; 3) conflict of interest (CoI) disclosure, and 4) expert evaluation of chapters. Methods: Contributors’ (N = 115) sex, professional degrees, and presence of undisclosed potential CoI as reported by the Center for Medicare and Medicaid’s Open Payments (2013 to 2017) were examined. Year of publication of citations were extracted relative to comparison textbooks (Katzung’s Basic and Clinical Pharmacology ( Kat BCP), and DiPiro’s Pharmacotherapy: A Pathophysiologic Approach ( DiP PAPA). Content experts in pharmacy and pharmacology education provided chapter reviews. Results: The percent of GG PBT contributors that were female (20.9%) was equivalent to those in Kat BCP (17.0%). Citations in GG PBT (11.5 ± 0.2 years) were significantly older than those in Kat BCP (10.4 ± 0.2) and DiP PAPA (9.1 ± 0.1, p < .0001). Contributors to GG PBT received three million in undisclosed remuneration from pharmaceutical companies (Maximum author = $743,718). In contrast, DiP PAPA made CoI information available. However, self-reported disclosures were not uniformly congruent with Open Payments reported data. Reviewers noted several strengths but also some areas for improvement. Conclusion: GG PBT will continue to be an important component of the biomedical curriculum. Areas of improvement include more diverse authorship, improved conflict of interest transparency, and greater inclusion of more recent citations.